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Shedding of membrane proteins
Barely 20 years have elapsed since our first description of membrane 
protein shedding as a general phenomenon in biology.1 Also described 
as ‘membrane protein solubilisation’ but now generally referred to as 
‘ectodomain shedding’, this is a process whereby proteins anchored in 
the cell membrane are cleaved and released by specialised proteases 
called ‘sheddases’. It is now estimated that up to 10% of all membrane 
proteins on somatic cells are processed in this way.2
Why is ectodomain shedding so widespread? Diverse types of 
membrane proteins are involved, most commonly adhesion proteins, 
various kinds of receptors, and cytokines and enzymes tethered to the 
cell surface. Ectodomain shedding allows for the rapid modulation of 
biological events on cell surfaces, especially cell-cell communication. 
In many cases, cell activation in response to endocrine or immune 
signals requires changes in cell-surface expression of receptors, 
adhesion molecules or cytokines, or the production of soluble forms 
of these proteins, and this is rapidly achieved by shedding.1 Many 
other physiological processes, from neural development to regulation 
of cell growth, also rely on shedding.
Given this ubiquity, it is not surprising that genetic disruption 
of one of the principal sheddases, ADAM17, is lethal during 
embryogenesis.2 We now know that there are many sheddases, 
although the most important appear to fall into 2 classes, both of 
which are zinc-dependent proteases: ADAM (a disintegrin and 
metalloproteinase) proteases, such as ADAM17 and ADAM10, 
and MMPs (matrix metalloproteases) (Fig. 1). There is significant 
interest in finding specific sheddase inhibitors, because of enormous 
pharmaceutical potential in diverse diseases, including auto-
immunity, cancer and Alzheimer’s disease.
The discovery of ACE shedding
Among membrane proteins that are shed, a significant proportion 
are cell surface enzymes, often called ecto-enzymes, including 
angiotensin-converting enzyme (ACE), which we were the first to 
show was spontaneously shed in a mammalian cell line.3 ACE is a 
large zinc-dependent protease that is a key component of the renin-
angiotensin system (RAS); ACE inhibitors are important drugs for 
the treatment of heart failure, hypertension, myocardial infarction, 
and diabetic nephropathy.4 ACE is widely expressed in endothelial 
and epithelial cells, where it is anchored in the cell membrane by a 
lipid-soluble domain near the C-terminal end of the protein. The 
enzyme can be viewed as having the shape of a lollipop: the bulk of 
the protein forms the globular part, which is connected via a stalk 
to the membrane anchor (Fig. 2). It is widely believed that it is the 
membrane-bound (‘tissue’) ACE that is principally responsible for 
its role within the RAS, although ACE was originally discovered as a 
soluble protein in plasma.
Soluble ACE is found in plasma, seminal fluid, cerebrospinal 
fluid and urine. Plasma ACE levels increase in certain inflammatory 
conditions, notably sarcoidosis, and it is believed the source is 
activated monocytes and macrophages.5 Elevated plasma ACE levels 
have also been linked to ACE gene polymorphisms, in some cases 
leading to very high plasma ACE levels. However, the role of soluble 
ACE in plasma is unclear. In terms of blood pressure regulation, 
studies in humans and in animals, including transgenic and knockout 
models, have shown that only the tissue-bound form is necessary and 
sufficient.6 It is more plausible that soluble ACE in plasma reflects a 
process whereby levels of tissue-bound ACE are being fine-tuned, 
thereby regulating local tissue RAS. If this is true, then soluble ACE 
is merely a byproduct of RAS regulation at the tissue level.
Despite the absence of definitive data, it is probable that soluble 
ACE has subtle biological functions in its own right. For example, 
soluble ACE in plasma offers a means for delivery of the enzyme 
to tissues that do not express their own ACE, thereby enabling 
local angiotensin II production with regional effects on vascular 
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tone and fluid and electrolyte homeostasis. Similarly, monocytes 
and macrophages expressing ACE may require both membrane-
bound and soluble forms for immune activation and regulation, as 
has been shown for other immune system proteins, such as TNFα 
and the receptors for TNFα 
and IL-6.2 In the male genital 
tract, a special isoform of 
ACE is expressed on the cell 
membrane of spermatozoa, but 
is later shed at a specific stage 
of spermatozoan maturation 
and appears in the seminal 
fluid. Again, the precise roles 
of the membrane-bound and 
soluble forms of the enzyme are 
poorly understood, but genetic 
disruption of germinal ACE in 
rodents leads to male infertility.6
The mechanism 
of ACE shedding
In our laboratory we have 
focused on the mechanism of 
ACE shedding: how does the 
sheddase recognise its target; 
where in the target protein 
does the cleavage occur; how 
is the process regulated; and 
what are the identities of the 
sheddases? As shown in Fig. 2, 
we now know that membrane 
proteins that are the targets of 
sheddases generally have a stalk 
that connects the ectodomain 
to the membrane anchor. This 
stalk is open and accessible 
and contains the cleavage site. 
This has led to the notion 
that sheddases function like 
lawnmowers that move over 
the surface of the cell and 
cut any protein stalks in their 
path. Although this is true in 
broad outline, our research 
indicates that sheddases follow 
certain rules: the sheddase not 
only looks for an open stalk 
but positions itself relative to 
the ectodomain and requires 
a minimum distance from 
the membrane.7 Even more 
intriguing is evidence that the 
sheddase binds to a ‘recognition 
domain’ in the target protein 
before cleaving the stalk.
Many of these concepts 
emerged from our work on ACE, 
in which we have the advantage 
of a natural experiment. As 
shown in Fig. 3, there are in fact 
2 kinds of ACE: the common 
form of the enzyme that is 
widely distributed (‘somatic ACE’) and an ACE variant, first cloned 
in our laboratory, which is only expressed in spermatozoa (‘testis 
ACE’). Somatic ACE contains 2 similar but distinct domains arranged 
in tandem: the second of the 2 domains (the C domain) is identical to 
Fig. 1. ADAM10 and ADAM17 are sheddases that play important roles in the regulation of cell migration and 
proliferation in cancer. Tumour cell migration and invasion are increased by ADAM10- and ADAM17-mediated 
shedding of cell adhesion molecules. Both sheddases also increase tumour proliferation due to the release of pro-EGFR 
ligands and EGFR transactivation. The figure was adapted from Saftig and Reiss.19
Fig. 2. Schematic representation of the ectodomain shedding of somatic and testis ACE isoforms. ACE domain structure 
is described in Fig. 3. The transmembrane domain (black coil) spans the lipid bilayer of the cell membrane. Cleavage of 
the stalk by the sheddase (green) leads to shedding. ACE gene mutations (red stars) P1199L, W1197Stop, and Y465D 
result in enhanced shedding and increased levels of soluble ACE in plasma.
Forum
463  June 2012, Vol. 102, No. 6  SAMJ
the bulk of the testis enzyme and both proteins share identical stalk, 
membrane, and cytoplasmic domains (Fig. 3). Despite this, shedding 
of testis ACE is much more efficient than shedding of somatic ACE. 
Why? Work from our and other laboratories has indicated that this 
is most likely because there is a sheddase recognition domain in the 
C domain of ACE, which in somatic ACE is partly occluded by the 
presence of the second domain (N domain).8,9 Indeed, when a mutant 
ACE was constructed in which the N domain of somatic ACE was 
fused directly to the stalk, this mutant was not shed, suggesting that 
it lacked a critical recognition element for the sheddase.9
Candidate ACE sheddases
The search for the ACE sheddase is ongoing. The 2 sheddases that 
are most widely implicated in shedding diverse membrane proteins 
– ADAM17 and ADAM10 – are not involved in ACE shedding.10 
The difficulty in identifying the ACE sheddase is partly because 
there are several alternate pathways and sheddases that contribute 
to this process. Interestingly, the ACE sheddase appears to be very 
similar (but not identical) to the so-called ‘α-secretase’, a sheddase 
that cleaves the amyloid precursor protein (APP), a protein that is 
implicated in the pathogenesis of Alzheimer’s disease. Although 
there does not appear to be a connection between ACE and APP, 
this similarity highlights the range of physiological and pathological 
processes in which shedding plays a role.
ACE mutations that affect ectodomain 
shedding and their implications
Recently, 3 novel ACE gene polymorphisms have been described that 
are associated with increased plasma ACE levels (see Figs 2 and 3).
First, a mutation was identified in subjects from studies of 
unrelated individuals in Europe.11 Patients with elevated plasma ACE 
had a single amino acid change in the stalk region (Pro1199Leu). 
Expression of recombinant ACE with this mutation in mammalian 
cells11 caused increased shedding of ACE, most likely because of 
a conformational change in the stalk allowing better access by the 
sheddase.
A second mutation in a family of African-Americans (W1197Stop)12 
results in a truncated ACE protein that lacks the membrane and 
cytoplasmic domains, leading to the direct production of soluble 
ACE and explaining the elevated plasma levels. The W1197Stop 
and Pro1199Leu mutations do not produce any apparent clinical 
pathology.
Collaboration of our group with the University of Chicago has 
revealed a third ACE mutation present in a family of individuals where 
the affected members suffer from intermittent nausea, vomiting, 
fatigue and depression.13 Investigation revealed dramatically elevated 
levels of plasma ACE (approximately 10-fold higher than normal) 
associated with a mutation in the ACE ectodomain (Y465D). 
Expression of recombinant ACE with this mutation in mammalian 
cells confirmed that the Y465D mutation causes increased ACE 
shedding.13 This is remarkable because the mutation is distant 
from the stalk cleavage site and probably causes a change in the 
relative orientation of the two domains, allowing better access of the 
sheddase.
The Y465D mutation is the first ACE polymorphism described 
that is associated with clinical pathology. Dysregulation of ACE 
expression and processing may produce the pathology by altering 
plasma levels of vaso- and neuropeptides degraded by ACE. A likely 
candidate is substance P, a peptide involved in pain and chronic 
inflammation, elevated plasma levels of which are associated with 
nausea, vomiting, depression and fatigue.14 ACE is one of the major 
enzymes involved in degradation of substance P,15 and symptomatic 
individuals with the Y465D mutation were shown to have elevated 
plasma substance P levels.13
ACE sheddases as therapeutic targets
The dynamics between the membrane-bound and soluble forms of 
ACE in the local and systemic renin-angiotensin systems are complex 
Fig. 3. The structural organisation of somatic and testis ACE proteins. The coloured bars are a schematic illustration of the organisation of the core protein 
domains. The 3 mutations found in patients that affect ectodomain shedding are indicated using the single-letter amino acid code and St for stop codon (see 
also Fig. 2). The black ovals denote the active sites with their characteristic zinc-binding motifs. The yellow box denotes a short unstructured linker region of 
approximately 14 residues that joins the N and C domains of somatic ACE.
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and a better understanding of the role played by the ACE sheddase(s) 
is still required. Moreover, unlike the systemic RAS, where renin 
secretion by the kidney plays an important regulatory role in the 
processing of angiotensinogen, it is not clear how the production of 
angiotensin II by the tissue RAS is controlled. In terms of therapeutic 
interventions, an important question is whether limiting the 
production of angiotensin II is best achieved by blocking the activity 
of ACE or by inhibiting its release from the cell membrane. While 
circulating ACE levels might have some clinical implications in certain 
diseases such as metabolic syndrome,16 tissue ACE is likely to be of 
more clinical significance in major cardiovascular diseases (CVD).17 
In general, blocking ACE activity by the use of conventional ACE 
inhibitors is likely to be most productive in mitigating CVD. However, 
inhibiting ACE shedding may offer novel therapeutic opportunities 
in situations in which increased local levels of angiotensin II, or 
other vaso- and neuropeptides, are useful. This concept of fine 
regulation of ACE activity at the tissue level is also being explored 
by an independent avenue of research in our laboratory – focused 
on specifically inhibiting single domains of somatic ACE, either the 
N or the C domain (current ACE inhibitors do not discriminate 
between the 2 domains). Recent studies have explored the different 
physiological roles of the N and C domain-active sites of ACE and 
have shown that inhibition of a single domain may be advantageous 
for targeting certain diseases, such as hypertension (C domain) and 
organ fibrosis (N domain), or for improving the side-effect profile of 
current non-selective ACE inhibitors.18
Conclusions
Shedding of membrane-bound ACE occurs in all mammalian species 
in which this has been studied and likely plays a critical role in 
regulating this enzyme at the cell and tissue levels. A more detailed 
picture of the process of ACE ectodomain shedding will not only 
further our understanding of the biology of ACE but also holds 
promise for novel therapeutic interventions. Beyond the shedding 
of ACE, sheddases affect a wide and emerging range of pathologies 
and thus are attractive targets for future therapeutic approaches. 
However, the number of target proteins and tissue distribution 
for each sheddase varies considerably, requiring care in selectively 
inhibiting a sheddase in an organ associated with a specific disease 
without affecting the function of the protease in other tissues. Despite 
this, there is optimism that sheddase inhibitors may be useful in auto-
immune diseases, malignancies, and neurodegenerative conditions.
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